EUCTR2019-001575-37-IT
Active, not recruiting
Phase 1
ong-term follow-up of adult Philadelphia chromosome negative acute lymphoblastic leukemia relapsed refractory patients enrolled in Study 00103311 - NA
ConditionsAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Adult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemia
- Sponsor
- AMGEN INC.
- Enrollment
- 75
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who were enrolled originally in the 00103311 trial (A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B\-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 80
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 28
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-term follow-up of adult patients previously enrolled in Study 00103311 with a type of acute lymphoblastic leukemia that did not respond to previous therapy or that relapsed after initially successful previous therapyAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-001575-37-DEAmgen Inc.108
Active, not recruiting
Phase 3
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and Blinatumomab, a specific monoclonal antibody, in adult patients, compared to the administration of chemotherapy and Imatinib. ALL28202023-508968-30-00Fondazione Gimema Franco Mandelli Onlus236
Active, not recruiting
Phase 1
ational Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategyational Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented StrategyTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-000383-18-ITG.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto204
Recruiting
Not Applicable
ong term follow up of the clinical and immunological responses following HPV 16 E6/E7 synthetic long peptides vaccination in women with HPV 16 positive vulvar intraepithelial neoplasia grade 3VINvulvair intraepithelial neoplasia10038594NL-OMON36101eids Universitair Medisch Centrum19
Recruiting
Not Applicable
ong term follow-up protocol of prospective cohort study on bone mineral density changes in the stage 1 or 2 gastric cancer patients after gastrectomygastric cancerJPRN-UMIN000043647Kindai University170